At ASCO, the CHRYSALIS-2 study read-out showed that patients on the combination had overall survival of nearly three-and-a-half years.

In combination with Keytruda, the antibody-drug conjugate slowed progression compared to anti-PD-1 therapy alone.

The trial missed its primary endpoint but showed the test can detect cancers earlier, fueling questions around the best framework to evaluate MCED tests.

NEW YORK – Natera and Diakonos Oncology on Friday announced a collaboration to use Natera's circulating tumor DNA (ctDNA) assay Signatera to longitudinally assess molecular response in Diakonos' Phase ...

Some patients have a mutation that causes them to not produce CA19-9, a tumor marker often used to help determine prognosis.

In addition to the beta-emitting yttrium-90 therapy, the company is also testing a yttrium-86 companion diagnostic in the Phase I trial.

The EXONERATE assay has demonstrated that it can predict outcomes and monitor resistance in colorectal cancer patients treated with EGFR inhibitors.

The firm will evaluate its adeno-associated virus-based gene therapy, TGX-007, in patients with newly diagnosed or recurrent tumors.

NEW YORK – The US Food and Drug Administration has requested additional data from AstraZeneca for its new drug application seeking approval for camizestrant for breast cancer patients with ESR1 ...

The VERVE-102 base editor appeared to be safe and reduce low-density lipoprotein cholesterol levels by up to 62 percent in a Phase I open-label, single-ascending dose trial.

The firm will evaluate the combination therapy in 80 patients with germline BRCA1/2-mutated HER2-negative locally advanced or metastatic breast cancer.